

## **Bioneer has decided on new rights issue to Yuhan Co., Ltd in a third party allocation**

- Bioneer Corporation announced on September 3<sup>rd</sup> that it will increase its capital via a third party allocation and issue new shares, all of which will be allocated to Yuhan Corporation Co., Ltd.
- In order to accelerate tangible accomplishments in new drug development based on its proprietary RNAi technology - SAMiRNA™ technology, Bioneer has pursued various partnerships with global pharmaceutical companies and decided to strengthen the business partnership with Korea no.1 pharmaceutical company, Yuhan Corporation Co., Ltd.
- Last June, Yuhan and Bioneer made an agreement on R&D collaboration for the development of cancer immunotherapy and companion diagnostics of immune markers. Both parties hope that concrete achievements will be obtained from the technology transfer and strategic partnership in the nearest future.
- Yuhan became the first domestic pharmaceutical company recorded 1 trillion won sales in 2014, and currently demonstrates no.1 sales performance in pharmaceutical business in Korea. Yuhan is continuously expanding R&D investment and reinforcing its pipeline to become a global pharmaceutical company via innovative new drug development.
- Bioneer will increase its capital by issuing common shares worth of 10 billion won and Yuhan is obliged to hold the shares for one year.